Eli Lilly to acquire AI drug developer

Eli Lilly is reportedly planning a substantial $2 billion deal to acquire a Hong Kong-based biotech firm specializing in artificial intelligence for drug development. This strategic move underscores the growing trend of major pharmaceutical companies leveraging AI to accelerate the discovery and creation of new medicines. The acquisition signals a significant investment in cutting-edge technology to enhance research and development pipelines. It also highlights China's increasing importance as a hub for biotech innovation and AI-driven pharmaceutical advancements.